Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19426188 | 0.84 | ADRB2 (0.39) | ALDH1A1SMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL15631155 | 0.83 | ALOX5 (0.53) | ALDH1A1ADRB2ADRB1ADRB3ALOX5 | |
| SCHEMBL15680669 | 0.81 | ADRA2A (0.39) | ALDH1A1ADRB2ADRB1ADRB3ADRA2A | |
| SCHEMBL19426020 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2ALOX5POLBCYP2C19 | |
| SCHEMBL15680140 | 0.77 | ADRA2A (0.36) | ALDH1A1ADRB2ADRB1ADRB3ALOX5 | |
| SCHEMBL15680139 | 0.75 | CES2 (0.42) | ALDH1A1SMN1; SMN2ADRB2ADRA2AADRA2B | |
| SCHEMBL17191831 | 0.75 | CES2 (0.38) | ADRB2ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL15631126 | 0.74 | KDM4E (0.44) | ADRB2ADRB1ADRB3ADRA2AADRA2B | |
| SCHEMBL19426094 | 0.73 | SMN1; SMN2 (0.40) | ALDH1A1SMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL15495180 | 0.71 | SELL (0.45) | ALDH1A1SMN1; SMN2ADRB2ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | ALDH1A1 1437/4885SMN1; SMN2 4325/4885ADRB2 2846/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | ALDH1A1 1437/4885SMN1; SMN2 4325/4885ADRB2 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.